Drugs / Acipimox
Acipimox
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02256722 | Oct → Nov 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT01488409 | May 2012 → Jan 2015 | hypertriglyceridemia | Massachusetts General Hospital | Completed | Missed primary |
| Phase 2 | NCT00449423 | Mar → Oct 2007 | heart failure | University of Aarhus | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03338387 | May 2003 → Dec 2007 overdue | bulimia nervosa | Charles University, Czech Republic | Enrolling by invitation | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01980524 | Oct 2013 → Dec 2015 | type 2 diabetes mellitus | Medical University of Vienna | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01816165 | Jun 2011 → Jun 2015 | type 1 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| Phase not applicable7 trials · 1 met primary | ||||||
| — | NCT02796950 | Jun 2016 → Jan 2017 | type 2 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| — | NCT01580813 | Jun 2011 → Jun 2015 | type 2 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01260376 | Apr 2011 → Sep 2012 | obesity disorder, type 2 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| — | NCT01299831 | Jan 2011 → Dec 2013 | — | University of Aarhus | Completed | No outcome recorded |
| — | NCT00943059 | Mar 2010 → Dec 2012 | dilated cardiomyopathy, type 2 diabetes mellitus | Maastricht University Medical Center | Completed | No outcome recorded |
| — | NCT00549614 | Oct 2007 → Dec 2008 | heart failure | University of Aarhus | Completed | No outcome recorded |
| — | NCT00246402 | Sep 2002 → Aug 2006 | HIV infectious disease, heart disorder, hyperlipidemia, hypertriglyceridemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Met primary |
| Comparator or background therapy6 trials | ||||||
| Phase 0 | NCT06229678 Background | Jan 2024 → Nov 2026 expected | symptomatic heart failure, type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00153179 Comparator | Sep 2005 → Dec 2011 | type 2 diabetes mellitus | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00759291 Comparator | Apr 2006 → Dec 2017 | metabolic syndrome X | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT03809793 Comparator | Jan 2020 → Jul 2023 | prediabetes syndrome | Liverpool John Moores University | Completed | No outcome recorded |
| — | NCT02782208 Comparator | Feb → Dec 2016 | glucose metabolism disease, hypopituitarism | University of Aarhus | Completed | No outcome recorded |
| — | NCT01209416 Comparator | Jun 2012 → Oct 2014 | hypopituitarism | University of Aarhus | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acipimox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03809793 ↗ |
| Known as | NSC-759818 | ChEMBL registry synonym — accepted as the source's own label CHEMBL345714 ↗ |
| Known as | Olbetam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01299831 ↗ |
| Action | Inhibit | “acipimox, a nicotinic acid derivative that impairs FFA efflux” PMID 31571412 ↗ Oct 2019 |
| Modality | Small molecule | “Acipimox, a nicotinic acid analogue and a potent inhibitor of lipolysis” NCT00246402 ↗ |
| Route | Oral | “acipimox 250 mg orally every 6 hours” NCT00153179 ↗ |